3D Biomimetic Spine Unit Model Through the Integration of Bioprinting and Transcriptomics (CDP-SUBT)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age30-70
SponsorI.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio

About this trial

The general objective of this project is to define the transcriptional profile of primary human cells derived from the nucleus pulposus (NP), annulus fibrosus (AF), and cartilaginous endplate (CEP), and to use this information as a reference to assess the biological relevance of a biomimetic spinal unit model obtained through bioprinting. By developing an in vitro model of human origin that incorporates key components of the spinal unit and applying transcriptional analyses to both native cells and their counterparts recovered from the 3D construct, the study will evaluate how accurately the bioprinted model reproduces the identity and heterogeneity of the native discal environment.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Signature of the Informed Consent for the study

Age 30-70 years (included)

Pfirrmann grade III-V

Need to undergo spinal surgery

Disqualifiers

Presence of HIV, HBC, HCV or TPHA infection

Trial population

Patient affected by Degenerative Disc disease undergoing spinal surgery

Trial design

Design model

Other

Time perspective

Cross-sectional

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Discovery of Tissue-Specific Molecular Markers in Intervertebral Disc Cellular Populations

To identify genes that are specifically upregulated in one of the three intervertebral disc cellular populations-nucleus pulposus (NP), annulus fibrosus (AF), and cartilaginous endplate (CEP)-through comparative gene expression analysis of paired samples obtained from the same donors. This aim seeks to determine tissue-specific molecular markers that will be subsequently applied to the characterization of bioprinted intervertebral disc models.

Time frame
From enrollment to data analysis (24 months)

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.